Genetic and Environmental Factors in the Response to Influenza Vaccination

PHASE1CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

October 3, 2014

Primary Completion Date

December 12, 2018

Study Completion Date

December 12, 2018

Conditions
InfluenzaHealthy
Interventions
BIOLOGICAL

FluMist® Quadrivalent

LAIV4 vaccine dosage is 0.2 mL. Vaccine will be administered as an intranasal spray. Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril. 0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position. Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger. The dose divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.

BIOLOGICAL

Fluzone® Quadrivalent vaccine

IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.

Trial Locations (1)

94305-5208

Stanford University, Stanford

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Stanford University

OTHER

NCT03088904 - Genetic and Environmental Factors in the Response to Influenza Vaccination | Biotech Hunter | Biotech Hunter